DNA methylation and type 2 diabetes: novel biomarkers for risk assessment?

GA Raciti, A Desiderio, M Longo, A Leone… - International Journal of …, 2021 - mdpi.com
Diabetes is a severe threat to global health. Almost 500 million people live with diabetes
worldwide. Most of them have type 2 diabetes (T2D). T2D patients are at risk of developing …

Lessons from neonatal β-cell epigenomic for diabetes prevention and treatment

A Abderrahmani, C Jacovetti, R Regazzi - Trends in Endocrinology & …, 2022 - cell.com
Pancreatic β-cell expansion and functional maturation during the birth-to-weaning period
plays an essential role in the adaptation of plasma insulin levels to metabolic needs. These …

Liquid biopsy in type 2 diabetes mellitus management: building specific biosignatures via machine learning

M Karaglani, M Panagopoulou, C Cheimonidi… - Journal of Clinical …, 2022 - mdpi.com
Background: The need for minimally invasive biomarkers for the early diagnosis of type 2
diabetes (T2DM) prior to the clinical onset and monitoring of β-pancreatic cell loss is …

Tissue-specific methylation biosignatures for monitoring diseases: an in silico approach

M Karaglani, M Panagopoulou, I Baltsavia… - International Journal of …, 2022 - mdpi.com
Tissue-specific gene methylation events are key to the pathogenesis of several diseases
and can be utilized for diagnosis and monitoring. Here, we established an in silico pipeline …

The importance of precision medicine in type 2 diabetes mellitus (T2DM): from pharmacogenetic and pharmacoepigenetic aspects

F Khatami, MR Mohajeri-Tehrani… - … , Metabolic & Immune …, 2019 - ingentaconnect.com
Background: Type 2 Diabetes Mellitus (T2DM) is a worldwide disorder as the most important
challenges of health-care systems. Controlling the normal glycaemia greatly profit long-term …

An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence

Y Lin, HR Kranzler, LA Farrer, H Xu… - The …, 2020 - nature.com
This study explored the effect of OPRM1 promoter region DNA methylation on the outcome
of treatment with the opioid antagonist naltrexone (NTX) for alcohol dependence (AD) …

Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review

L Karkhaneh, O Tabatabaei-Malazy… - Journal of Diabetes & …, 2022 - Springer
Purpose Genetic factors have a role in response to a target medication (personalized
medicine). This study aimed to review available evidence about the relationship between …

Determinants in tailoring antidiabetic therapies: a personalized approach

AA Rizvi, M Abbas, S Verma, S Verma… - Global Medical …, 2022 - thieme-connect.com
Diabetes has become a pandemic as the number of diabetic people continues to rise
globally. Being a heterogeneous disease, it has different manifestations and associated …

[PDF][PDF] Relationship between the efficacy of sulfonylurea therapy and structural variants of the ABCC8 (rs757110) and KCNJ11 (rs5219) genes in patients with type 2 …

IA Bondar, ML Filipenko, OY Shabel'nikova… - Оригинальные …, 2024 - sibmed.elpub.ru
Recently, a large number of studies have been conducted to investigate the variability of
response in the treatment of diabetes mellitus (T2DM), which make personalized medicine …

Взаимосвязь эффективности терапии препаратами сульфонилмочевины со структурными вариантами генов ABCC8 (rs757110) и KCNJ11 (rs5219) у больных …

ИА Бондарь, МЛ Филипенко… - Сибирский научный …, 2024 - sibmed.elpub.ru
Аннотация В последнее время проводится большое количество исследований,
направленных на изучение вариабельности ответа при лечении cахарного диабета 2 …